384 related articles for article (PubMed ID: 32506946)
1. Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection.
Otamas A; Grant PJ; Ajjan RA
Diab Vasc Dis Res; 2020; 17(3):1479164120920582. PubMed ID: 32506946
[TBL] [Abstract][Full Text] [Related]
2. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus.
Soma P; Pretorius E
Cardiovasc Diabetol; 2015 Jul; 14():96. PubMed ID: 26228646
[TBL] [Abstract][Full Text] [Related]
3. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.
Kaur R; Kaur M; Singh J
Cardiovasc Diabetol; 2018 Aug; 17(1):121. PubMed ID: 30170601
[TBL] [Abstract][Full Text] [Related]
4. Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation.
Bryk-Wiązania AH; Undas A
Cardiovasc Diabetol; 2021 Sep; 20(1):191. PubMed ID: 34551784
[TBL] [Abstract][Full Text] [Related]
5. Diabetes mellitus as a prothrombotic condition.
Grant PJ
J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
[TBL] [Abstract][Full Text] [Related]
6. Smoking, haemostatic factors, and cardiovascular risk.
Leone A
Curr Pharm Des; 2007; 13(16):1661-7. PubMed ID: 17584096
[TBL] [Abstract][Full Text] [Related]
7. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.
Ten Cate H; Guzik TJ; Eikelboom J; Spronk HMH
Cardiovasc Res; 2021 Jul; 117(9):2030-2044. PubMed ID: 32931586
[TBL] [Abstract][Full Text] [Related]
8. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.
Kearney K; Tomlinson D; Smith K; Ajjan R
Cardiovasc Diabetol; 2017 Mar; 16(1):34. PubMed ID: 28279217
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study.
Hannemann J; Laing A; Middleton B; Schwedhelm E; Marx N; Federici M; Kastner M; Skene DJ; Böger R
Pharmacol Res; 2024 Jan; 199():107011. PubMed ID: 38029806
[TBL] [Abstract][Full Text] [Related]
10. [Diabetes mellitus and prothrombotic activity].
Malý J
Vnitr Lek; 2010 Apr; 56(4):284-8. PubMed ID: 20465096
[TBL] [Abstract][Full Text] [Related]
11. Diabetes mellitus and thrombosis.
Vazzana N; Ranalli P; Cuccurullo C; Davì G
Thromb Res; 2012 Mar; 129(3):371-7. PubMed ID: 22197180
[TBL] [Abstract][Full Text] [Related]
12. BMAL1-Downregulation Aggravates
Xie M; Tang Q; Nie J; Zhang C; Zhou X; Yu S; Sun J; Cheng X; Dong N; Hu Y; Chen L
Circ Res; 2020 Mar; 126(6):e15-e29. PubMed ID: 32078488
[TBL] [Abstract][Full Text] [Related]
13. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
[TBL] [Abstract][Full Text] [Related]
14. [Atherothrombosis in patients with type 2 diabetes mellitus: an overview of pathophysiology].
Mafrici A; Proietti R
G Ital Cardiol (Rome); 2010 Jun; 11(6):467-77. PubMed ID: 20922872
[TBL] [Abstract][Full Text] [Related]
15. New insights into the role of adipose tissue in thrombosis.
Vilahur G; Ben-Aicha S; Badimon L
Cardiovasc Res; 2017 Jul; 113(9):1046-1054. PubMed ID: 28472252
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome, haemostasis and thrombosis.
Alessi MC; Juhan-Vague I
Thromb Haemost; 2008 Jun; 99(6):995-1000. PubMed ID: 18521499
[TBL] [Abstract][Full Text] [Related]
17. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis.
Antoniades C; Tousoulis D; Marinou K; Papageorgiou N; Bosinakou E; Tsioufis C; Stefanadi E; Latsios G; Tentolouris C; Siasos G; Stefanadis C
Clin Cardiol; 2007 Jun; 30(6):295-300. PubMed ID: 17551966
[TBL] [Abstract][Full Text] [Related]
18. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.
Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148
[TBL] [Abstract][Full Text] [Related]
19. The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease.
Shen S; Liao Q; Wong YK; Chen X; Yang C; Xu C; Sun J; Wang J
Int J Biol Sci; 2022; 18(3):983-994. PubMed ID: 35173531
[TBL] [Abstract][Full Text] [Related]
20. On the role of coagulation and fibrinolysis in atherosclerosis.
Juhan-Vague I; Collen D
Ann Epidemiol; 1992 Jul; 2(4):427-38. PubMed ID: 1342293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
